Ozempic Pancreatitis Lawsuit

Semaglutide operates through a sophisticated mechanism that fundamentally alters several digestive and metabolic processes within the body.

As a GLP-1 receptor agonist sharing 94% structural homology with human GLP-1, the medication binds to and activates receptors located primarily in the gastrointestinal tract, pancreas, and brain, triggering a cascade of physiological responses that extend far beyond simple blood sugar control.

Ozempic triggers multiple physiological responses throughout the body, primarily affecting these systems:

• Insulin Secretion Enhancement: Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose levels, providing glucose-dependent control that reduces hypoglycemia risk
• Glucagon Suppression: Reduces the release of glucagon from pancreatic alpha cells, preventing the liver from producing excess glucose during meals
• Gastric Emptying Delay: slows the rate at which food moves from the stomach to the small intestine, creating prolonged feelings of fullness
• Appetite Regulation: Acts on brain centers controlling hunger and satiety, reducing overall food intake and cravings
• Hepatic Glucose Production: Decreases the liver’s glucose output through both direct and indirect mechanisms

The medication achieves its effects through once-weekly subcutaneous injections, with the FDA approving doses of 0.5 mg and 1.0 mg for diabetes management.

While the FDA approved doses of 0.5 mg and 1.0 mg for diabetes management, the agency has also issued warnings about potential risks including pancreatitis, thyroid cancer concerns based on animal studies, and other serious adverse events.

According to FDA prescribing information, patients typically start with 0.25 mg weekly for four weeks before increasing to therapeutic doses.

The drug’s half-life of approximately one week allows for convenient weekly dosing, but this extended presence in the body also means that adverse effects, particularly those affecting gastric motility, can persist and potentially worsen over time.

The delayed stomach emptying mechanism, while contributing to weight loss and improved glycemic control, has emerged as a particular concern in litigation.

This slowing of stomach motility can progress from a therapeutic effect to a pathological condition, potentially triggering a cascade of gastrointestinal complications.

Rise in Off-Label Weight Loss Drug Prescriptions and Usage Patterns

The transformation of Ozempic from a diabetes prescription drug to a weight loss phenomenon represents one of the most dramatic shifts in pharmaceutical prescribing patterns in recent history.

What began as anecdotal reports of weight loss among diabetic patients quickly evolved into a full-scale cultural movement, driven by celebrity endorsements, social media virality, and aggressive off-label prescribing that fundamentally changed the drug’s user demographics and market positioning.

The surge in off-label Ozempic prescriptions has created unprecedented market disruptions, as evidenced by:

• Dramatic Prescription Shifts: Analysis of prescribing data shows that while over 90% of Ozempic prescriptions in 2018 were for type 2 diabetes, this figure dropped to just 58% by 2023, indicating massive off-label use
• Celebrity and Social Media Influence: High-profile endorsements from celebrities like Oprah Winfrey, Amy Schumer, and Chelsea Handler sparked unprecedented demand, with the hashtag #Ozempic generating millions of views on TikTok, often downplaying potential gastrointestinal issues associated with the medication
• Supply Shortages: The surge in off-label prescribing created nationwide drug shortages lasting through 2024, leaving diabetic patients unable to access their prescribed medication
• Cosmetic Weight Loss Usage: Many new users sought the medication purely for aesthetic weight loss rather than medical necessity, often without meeting clinical criteria for obesity treatment

The social media phenomenon surrounding Ozempic fundamentally altered public perception of prescription medications.

Platforms like TikTok and Instagram became virtual marketplaces where users documented their weight loss journeys in real-time, creating a feedback loop that drove ever-increasing demand.

According to research published in the Journal of Medicine, Surgery, and Public Health, content analysis of TikTok videos revealed that users predominantly focused on weight loss benefits while minimizing or ignoring discussion of serious health risks and side effects.

Increasing Prescribing Pressure for GLP 1 Drugs

The prescribing shift has created particular challenges for healthcare providers attempting to balance patient demands with medical ethics and drug availability, while drug manufacturers continued marketing campaigns despite mounting safety concerns.

Many physicians report feeling pressured to prescribe Ozempic off-label to patients clamoring for the medication after seeing dramatic transformations on social media, despite serious concerns about potential complications.

This pressure has led to prescribing decisions that may not fully account for individual risk factors, including susceptibility to pancreatic inflammation and gastrointestinal complications.

Market analysis reveals that the off-label prescribing boom generated billions in additional revenue for manufacturer Novo Nordisk, even as reports of serious adverse events began accumulating and lawsuits claim the company prioritized profits over patient safety.

The company’s marketing strategies, while not explicitly promoting off-label use, capitalized on the weight loss buzz through carefully crafted messaging that emphasized the medication’s “metabolic benefits” beyond blood sugar control.

Internal documents emerging through litigation discovery suggest the company failed to implement stronger safety warnings about gastrointestinal risks despite being well aware of the off-label prescribing trends and choosing to prioritize market expansion.

Unlike the original diabetic patient population, many off-label users are younger, healthier individuals without the metabolic dysfunction that might warrant acceptance of serious side effect risks.

These patients, seeking primarily cosmetic benefits, may have been inadequately counseled about the potential for developing conditions like pancreatitis that can trigger cascading gastrointestinal complications including gastroparesis.

The emergence of pancreatitis in this population raises questions about whether the drug’s risk-benefit profile was appropriately communicated and whether additional warnings should have been implemented as prescribing patterns shifted.

If you or a loved one developed pancreatitis or gastroparesis after taking Ozempic for any purpose, including off-label weight loss, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to join others in filing an Ozempic pancreatitis lawsuit today.

Medical research has established a concerning connection between Ozempic use and the development of pancreatitis, a serious inflammatory condition that can progress to cause gastroparesis – the actual compensable injury in ongoing litigation.

The relationship between these conditions represents a cascade of gastrointestinal dysfunction, where pancreatitis-induced damage to the pancreas disrupts normal digestive processes and can lead to permanent gastric motility disorders.

Clinical Evidence and Scientific Studies

A landmark 2023 study published in the Journal of the American Medical Association revealed alarming statistics about the gastrointestinal risks associated with GLP-1 receptor agonists like Ozempic, particularly when used for weight loss purposes.

The research (which analyzed data from millions of patients) found that individuals taking these medications faced dramatically elevated risks for multiple severe gastrointestinal conditions that often occur in sequence – beginning with pancreatitis and potentially progressing to gastroparesis.

Research findings reveal substantially elevated gastrointestinal risks demonstrating:

• Pancreatitis Risk: Patients using GLP-1 agonists showed a 9.09-fold increased risk (adjusted hazard ratio) for developing pancreatitis compared to those using alternative weight loss medications
• Gastroparesis Development: The study revealed a 3.67-fold increased risk for gastroparesis, often occurring secondary to pancreatic inflammation
• Bowel Obstruction: A 4.22-fold increased risk for intestinal blockages was documented, frequently accompanying severe gastroparesis cases
• FDA Adverse Event Reports: Analysis of the FDA’s FAERS database through 2024 shows over 900 reported cases of pancreatitis specifically linked to semaglutide use
• Post-Marketing Surveillance: Real-world data from 2023-2024 indicates that serious gastrointestinal events occur more frequently than initially reported in clinical trials

When pancreatitis develops, the inflamed pancreas releases numerous enzymes, toxic substances, and vasoactive compounds including inflammatory cytokines that can damage the autonomic nervous system controlling gastric function.

Studies examining gastric emptying in pancreatitis patients have revealed that the inflammatory process disrupts the intricate coordination between the pancreas and stomach.

The vagus nerve, which controls gastric motility, can become damaged during episodes of pancreatitis, leading to persistent delayed gastric emptying even after the acute inflammation resolves.

This explains why many Ozempic users who develop pancreatitis subsequently experience chronic gastroparesis symptoms that persist long after discontinuing the medication.

The temporal relationship between Ozempic use, pancreatitis onset, and gastroparesis development has been documented in numerous case reports submitted to regulatory agencies.

Patients typically develop acute pancreatitis within weeks to months of initiating Ozempic therapy, with gastroparesis symptoms emerging either during the acute phase or in the subsequent recovery period, forming the basis of many lawsuit claims.

The FDA’s analysis of adverse event timing patterns shows that approximately 40% of patients who develop pancreatitis while taking Ozempic subsequently report symptoms consistent with gastroparesis, including:

• Severe nausea;
• Vomiting;
• Early satiety; and
• Abdominal pain that persists for months or becomes permanent.

Recent pharmacovigilance studies utilizing advanced data mining techniques have identified semaglutide as having one of the strongest associations with both pancreatitis and subsequent gastroparesis among all diabetes medications.

The consistency of this finding across multiple databases, countries, and patient populations strengthens the evidence for a causal relationship rather than mere association.

Types of Pancreatitis Associated with Ozempic Use

The spectrum of pancreatitis cases linked to Ozempic use ranges from mild acute episodes to life-threatening necrotizing forms, each carrying different risks for progression to gastroparesis and other permanent complications.

Medical professionals have identified five distinct forms of pancreatitis in Ozempic users, each carrying different prognoses:

• Acute Pancreatitis: The most common form, affecting 80% of cases, characterized by sudden inflammation that typically resolves but can trigger lasting motility disorders with mortality rates below 2% in mild cases
• Necrotizing Pancreatitis: Occurring in 20-30% of severe cases, involving tissue death within the pancreas that increases the risk of permanent gastroparesis, with mortality rates ranging from 15-30%
• Hemorrhagic Pancreatitis: A severe variant specifically mentioned in FDA’s 2025 updated warnings, involving bleeding within the pancreas and carrying mortality rates exceeding 30%
• Chronic Pancreatitis: Progressive inflammation leading to permanent scarring and dysfunction, strongly associated with persistent gastroparesis development

The FDA’s January 2025 update to the ozempic warning label specifically added warnings about “fatal and non-fatal hemorrhagic or necrotizing pancreatitis” and other serious adverse events including anterior ischemic optic neuropathy, acknowledging the serious nature of these complications.

According to data from the National Institute of Diabetes and Digestive and Kidney Diseases, necrotizing pancreatitis causes permanent damage to pancreatic tissue in over 50% of cases – creating lasting disruptions to the digestive system’s neural and hormonal control mechanisms.

The progression from pancreatitis to gastroparesis follows predictable patterns based on the type and severity of pancreatic inflammation.

In acute pancreatitis cases, transient gastroparesis may occur during the inflammatory phase but can become permanent if pancreatic damage affects the cells producing digestive hormones or damages the autonomic nerves.

Hemorrhagic pancreatitis (now specifically warned about on Ozempic’s label) presents unique risks for gastroparesis development due to the additional vascular damage involved.

The bleeding within pancreatic tissue can compromise blood flow to surrounding organs, including portions of the stomach and duodenum, potentially causing ischemic injury that further impairs gastric motility.

Patients who survive hemorrhagic pancreatitis frequently report persistent digestive symptoms consistent with severe gastroparesis, including (but not limited to):

• Inability to tolerate solid foods;
• Chronic nausea;
• Nutritional deficiencies requiring long-term medical management; and (in some cases)
• Cardiovascular complications such as deep vein thrombosis (DVT).

The severity stratification of pancreatitis has important implications for legal claims.

Patients who developed necrotizing or hemorrhagic pancreatitis while taking Ozempic typically have stronger cases due to the objective evidence of tissue damage visible on imaging studies and the higher likelihood of permanent complications.

Medical records documenting elevated inflammatory markers, CT or MRI evidence of pancreatic necrosis, extended hospitalizations, and the development of subsequent gastroparesis create compelling evidence for causation in litigation.

If you or a loved one experienced severe abdominal pain, persistent vomiting, or other concerning symptoms while taking Ozempic that led to a pancreatitis diagnosis and subsequent gastroparesis, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to join others in filing an Ozempic lawsuit today.

The challenge lies in distinguishing between common Ozempic side effects and the more serious symptoms of developing pancreatitis, as both conditions share overlapping gastrointestinal symptoms including nausea, vomiting, and abdominal discomfort.

This similarity often leads to dangerous delays in diagnosis, as patients experiencing stomach pain and healthcare providers may initially attribute symptoms to expected medication side effects rather than recognizing them as signs of pancreatic inflammation.

Prompt medical evaluation with appropriate diagnostic testing can identify pancreatitis before it progresses to cause permanent damage, including the development of gastroparesis that forms the basis of current litigation against Novo Nordisk.

Early Warning Signs and Symptom Progression

The onset of pancreatitis in Ozempic users often begins subtly, with symptoms that closely mirror the medication’s known gastrointestinal side effects, creating a dangerous diagnostic challenge that can delay treatment.

Patients experiencing pancreatitis from Ozempic report symptoms that distinctly differ from routine side effects in the following ways:

• Severe Upper Abdominal Pain: Unlike typical Ozempic discomfort, pancreatitis pain is intense, penetrating, and often described as the worst pain patients have experienced, typically radiating to the back
• Persistent Nausea and Vomiting: While common with Ozempic, pancreatitis-related symptoms don’t improve with time and may worsen after eating, becoming debilitating
• Abdominal Tenderness: Physical examination reveals tenderness to touch, often with guarding or rigidity, distinguishing it from typical medication-related discomfort
• Position-Dependent Pain: Patients often find relief by leaning forward or drawing knees to chest, a characteristic sign of pancreatic inflammation
• Progressive Symptom Intensity: Unlike medication side effects that typically stabilize, pancreatitis symptoms progressively worsen over hours to days

Research published in medical journals indicates that the average time from symptom onset to emergency department presentation is 24-72 hours, with many patients initially attempting to manage symptoms at home believing they’re experiencing expected Ozempic side effects.

This delay can be catastrophic, as acute pancreatitis can rapidly progress to necrotizing forms that increase the risk of developing permanent gastroparesis.

The overlap between Ozempic’s gastrointestinal effects and pancreatitis symptoms creates particular diagnostic challenges.

These advanced symptoms indicate severe pancreatitis with high risk for complications including gastroparesis development.

The transition from acute pancreatitis to gastroparesis symptoms can occur during the acute phase or emerge weeks later.

Patients report that even after pancreatitis pain subsides, they experience persistent nausea, early satiety, bloating, and inability to tolerate normal meals – classic signs of gastroparesis.

If you or a loved one experienced severe abdominal pain, persistent vomiting, or other concerning symptoms while taking Ozempic that led to a pancreatitis diagnosis and subsequent gastroparesis, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to join others in filing an Ozempic lawsuit today.

Diagnostic Procedures and Medical Evaluation Process

The diagnostic journey for pancreatitis in Ozempic users requires specific laboratory tests and imaging studies that can definitively identify pancreatic inflammation and assess its severity, factors in documenting the pathway to gastroparesis development.

Healthcare providers must maintain high clinical suspicion for pancreatitis in any Ozempic user presenting with severe abdominal symptoms, as delayed diagnosis increases the risk of complications including permanent gastric motility disorders that form the basis of ongoing litigation.

Healthcare providers must conduct comprehensive testing to definitively diagnose pancreatitis and assess its severity through:

• Serum Lipase Testing: The gold standard diagnostic marker, with levels three times above normal indicating pancreatitis, remaining elevated for 8-14 days providing a wider diagnostic window than amylase
• Serum Amylase Measurement: Rises within 3-6 hours of onset but normalizes within 5 days, making it less reliable for delayed presentations common in Ozempic users
• Magnetic Resonance Imaging (MRI): Superior to CT for detecting early pancreatic changes and assessing ductal anatomy, with 92% diagnostic sensitivity
• Gastric Emptying Scintigraphy: Four-hour solid-phase study required to diagnose gastroparesis, typically performed after acute pancreatitis resolution when motility symptoms persist
• Complete Metabolic Panel: Evaluates organ function, electrolyte imbalances, and severity markers including BUN, creatinine, and calcium levels

According to guidelines from the American College of Gastroenterology, the diagnosis of acute pancreatitis requires two of three criteria:

1. Characteristic abdominal pain;
2. Serum lipase or amylase elevated three times above normal; or
3. Characteristic imaging findings.

Other Ozempic-related conditions, like ischemic optic neuropathy (NAION), require separate ophthalmologic evaluation.

However, the diagnostic challenge in Ozempic users stems from the potential for delayed presentation, as patients may initially attribute symptoms to expected medication side effects, arriving at emergency departments after enzyme levels have begun to normalize.

Lipase testing has emerged as the preferred diagnostic tool due to its superior sensitivity and prolonged elevation compared to amylase.

Studies show lipase remains elevated for up to two weeks after pancreatitis onset, important for Ozempic users who may delay seeking care.

The magnitude of enzyme elevation doesn’t correlate with severity; however, persistently elevated levels suggest ongoing inflammation with higher risk for complications including gastroparesis development.

Imaging plays an important role in both diagnosis and prognosis.

While initial ultrasound may show gallstones or pancreatic enlargement, contrast-enhanced CT performed 72-96 hours after symptom onset best identifies pancreatic necrosis – visible in only 30% of cases initially but important for predicting gastroparesis risk.

The modified CT Severity Index (CTSI) scores help stratify patients, with scores above 8 indicating severe disease with mortality rates approaching 20% and high likelihood of permanent complications.

Patients who developed pancreatitis leading to gastroparesis after taking Ozempic possess legal rights to pursue compensation for their injuries, medical expenses, and life-altering complications through the federal MDL proceedings.

The law recognizes that pharmaceutical companies have a duty to provide adequate warnings about medication risks, and when this duty is breached, injured patients deserve compensation for the full scope of their damages.

Settlement projections for Ozempic cases involving the pancreatitis-to-gastroparesis progression range from $400,000 to over $1 million, depending on injury severity, medical expenses incurred, the degree of permanent impairment, and the strength of failure to warn claims against the manufacturer.

The settlement amounts mentioned above are estimations only and not guaranteed.

These projections are based on legal experts’ analysis of similar pharmaceutical litigation cases and the nature of injuries involved.

Individual case values vary based on specific circumstances, medical documentation, and injury severity.

These figures should be used only as general reference points and not as promises or guarantees of compensation.

Contact TruLaw using the chat on this page for an individualized case evaluation.

Types of Recoverable Damages and Compensation

The compensation structure for Ozempic lawsuits recognizes the comprehensive impact that pancreatitis and resulting gastroparesis have on patients’ lives, encompassing both economic losses and non-economic suffering that can persist for years or permanently.

Legal experts analyzing the litigation project that cases involving documented progression from pancreatitis to gastroparesis may command higher settlements due to the clear causal pathway and objective medical evidence supporting the injury claims.

Ozempic litigation recognizes comprehensive compensation categories that reflect the full impact of pancreatitis and resulting gastroparesis:

• Medical Expenses: Coverage for emergency room visits, hospitalizations for pancreatitis treatment, diagnostic testing including CT scans and gastric emptying studies, surgical interventions, feeding tube placement, and ongoing gastroparesis management
• Future Medical Costs: Compensation for anticipated lifelong treatment needs, medical monitoring for pancreatic function, nutritional support, prescription medications, and potential surgical procedures
• Lost Wages and Earning Capacity: Recovery for time missed from work during acute pancreatitis episodes, ongoing disability from gastroparesis symptoms, reduced earning potential due to chronic illness, and early retirement forced by permanent disability
• Pain and Suffering: Compensation for physical pain from pancreatitis and gastroparesis, chronic nausea and vomiting, inability to enjoy meals, and diminished quality of life
• Emotional Distress: Damages for depression, anxiety, social isolation due to dietary restrictions, and psychological impact of living with an incurable digestive disorder
• Wrongful Death Damages: For families who lost loved ones to severe pancreatitis complications, including funeral expenses, loss of companionship, and lost financial support

Settlement valuations emerging from early case assessments suggest a tiered structure based on injury severity and documented damages.

Mild cases involving temporary gastroparesis that resolved after pancreatitis treatment may see settlements in the $100,000 to $250,000 range.

However, severe cases involving necrotizing pancreatitis progressing to permanent gastroparesis requiring feeding tubes or surgical intervention could exceed $700,000 to $1 million, particularly when patients can demonstrate complete lifestyle disruption and ongoing medical needs.

The economic damages component often forms the foundation of settlement calculations, as medical bills from emergency treatment, hospitalizations, ongoing care, lost wages from pancreatitis and gastroparesis treatment can rapidly accumulate.

Emergency hospitalization for acute pancreatitis averages $10,000 to $30,000, while severe cases involving complications like acute kidney injury and requiring intensive medical intervention and ICU care can exceed $100,000.

Subsequent gastroparesis management, including regular physician visits, medications, nutritional counseling, and potential surgical interventions, can cost $20,000 to $50,000 annually.

Please note that all settlement ranges mentioned above are preliminary estimates based on legal experts’ opinions and analysis of similar pharmaceutical litigation.

These figures are not guaranteed outcomes and should not be interpreted as promises of specific compensation amounts.

If you or a loved one developed pancreatitis that progressed to gastroparesis or other permanent complications after taking Ozempic, you may be eligible to seek compensation for all categories of damages.

For an accurate assessment of your specific case value, contact TruLaw using the chat on this page to receive a personalized case evaluation.

Eligibility Criteria and Case Evaluation Process

Determining eligibility for an Ozempic lawsuit requires meeting specific criteria that establish the connection between medication use, pancreatitis development, and subsequent gastroparesis or other compensable injuries.

TruLaw’s streamlined case evaluation process offers a free consultation to help potential plaintiffs quickly determine whether they qualify to recover financial compensation while ensuring all necessary documentation is gathered to support their claims in the ongoing legal proceedings.

To qualify for an Ozempic lawsuit, potential plaintiffs must meet several specific criteria (though additional factors may apply):

• Medication Usage: Documented prescription and use of Ozempic, Wegovy, Rybelsus, or other semaglutide medications for diabetes management or weight loss, with pharmacy records confirming dispensing
• Pancreatitis Diagnosis: Medical confirmation of acute, chronic, necrotizing, or hemorrhagic pancreatitis through elevated lipase/amylase levels and imaging studies showing pancreatic inflammation
• Gastroparesis Development: Diagnosis of delayed gastric emptying through scintigraphy testing or clinical symptoms persisting after pancreatitis resolution, documented in medical records
• Temporal Relationship: Symptoms occurring within a reasonable timeframe after starting Ozempic, typically within 60 days to six months, establishing causal connection
• Medical Documentation: Comprehensive records including emergency room visits, hospitalization records, diagnostic test results, and ongoing treatment for both pancreatitis and gastroparesis
• No Prior Settlement: Confirmation that no previous compensation has been accepted or liability waiver signed releasing Novo Nordisk from responsibility

The statute of limitations presents a consideration for potential plaintiffs seeking legal counsel, as each state imposes different deadlines for filing product liability claims.

These deadlines typically range from one to three years from the date of injury discovery – meaning when the connection between Ozempic and the pancreatitis-gastroparesis progression was recognized.

Some states apply the discovery rule, which extends the filing deadline to when a reasonable person would have discovered the medication caused their injuries, potentially providing additional time for patients who didn’t immediately connect their symptoms to Ozempic use.

TruLaw’s instant case evaluation system streamlines the eligibility determination process through a comprehensive yet efficient approach.

The evaluation begins with basic information gathering about Ozempic usage, including start date, dosage, and prescribing purpose, guiding clients through the legal process step by step.

Next, detailed health history focusing on pancreatitis diagnosis, gastroparesis symptoms, and medical treatment received is collected.

Documentation requirements are explained, helping clients understand what records strengthen their claims.

Our Ozempic attorney at TruLaw is dedicated to supporting clients through the process of filing an Ozempic lawsuit.

With extensive experience in dangerous drug and pharmaceutical litigation cases, Jessica Paluch-Hoerman and our partner law firms work with litigation leaders and medical experts to prove how Ozempic (semaglutide) injections caused you harm.

TruLaw focuses on securing compensation for medical expenses, hospitalization costs, lost wages, pain and suffering, and other damages resulting from your Ozempic-related injuries including gastroparesis, intestinal blockages, gallbladder issues, and other severe gastrointestinal complications.

We understand the physical and emotional toll that Ozempic complications have on your life and provide the personalized guidance you need when seeking justice.

Meet the Lead Ozempic Attorney at TruLaw

Meet our lead Ozempic attorney:

• Jessica Paluch-Hoerman: As founder and managing attorney of TruLaw, Jessica brings her experience in pharmaceutical litigation and personal injury to her client-centered approach by prioritizing open communication and personalized attention with her clients. Through TruLaw and partner law firms, Jessica has helped collect over $3 billion on behalf of injured individuals across all 50 states through verdicts and negotiated settlements.

How much does hiring an Ozempic lawyer from TruLaw cost?

At TruLaw, our experienced legal team believes financial concerns should never stand in the way of justice.

That’s why we operate on a contingency fee basis – with this approach, you only pay legal fees after you’ve been awarded compensation for your injuries.

If you or a loved one experienced severe gastrointestinal complications, gastroparesis, intestinal blockages, gallbladder problems, or other serious health complications after using Ozempic for diabetes management or weight loss, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to join others in filing an Ozempic lawsuit today.

Individuals across the country who suffered severe gastrointestinal complications and other serious health issues after using the diabetes and weight-loss medication have filed lawsuits against the manufacturer.

TruLaw is currently accepting clients for the Ozempic lawsuit.

A few reasons to choose TruLaw for your Ozempic lawsuit include:

• If We Don’t Win, You Don’t Pay: The Ozempic lawyers at TruLaw and our partner firms who have successfully represented clients who filed ozempic lawsuits operate on a contingency fee basis, meaning we only get paid if you win.
• Expertise: We have decades of experience handling dangerous drugs cases similar to the Ozempic lawsuit.
• Successful Track Record: TruLaw and our partner law firms have helped our clients recover billions of dollars in compensation through verdicts and negotiated settlements.

If you or a loved one developed gastroparesis, intestinal blockages, gallbladder problems, persistent vomiting, or other severe gastrointestinal complications after using Ozempic for diabetes management or weight loss, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify to join others in filing an Ozempic lawsuit today.